US EditionPfizer completes up to $10 billion acquisition of Metsera
Pfizer’s $10 billion acquisition of Metsera secures obesity drug pipeline, aiming to compete in a $150–$200 billion global weight-loss market, CEO Albert Bourla said.
- Pfizer Inc. said Thursday it completed its $10 billion acquisition of Metsera after a fierce, months-long bidding contest with Novo Nordisk.
- Seeking to enter the GLP-1 market, Pfizer said it secures rights to new weight-loss treatments still in trials, aiming for a share of an estimated $150 to $200 billion market.
- The deal paid $65.60 per share in cash plus $20.65 per share contingent on pipeline success, and could reach up to $86.25 per share under the terms, Pfizer said.
- Metsera shareholders approved the sale, clearing the way for Pfizer to advance candidates, and Pfizer expects its first weight-loss treatment by the end of 2028.
- The company is aligning Metsera drugs with the Trump administration's TrumpRx platform, and Albert Bourla said, `I think the TrumpRx that he just spoke about is a wonderful opportunity for Americans to receive medicines at a fraction of the cost.
30 Articles
30 Articles
Pfizer Completes Acquisition of Metsera, Ending Hotly Contested Bidding Offer
Pharmaceutical maker Pfizer announced on Nov. 13 that it had completed its $10 billion acquisition of Metsera, ending a convoluted bidding war for the clinical-stage obesity biotech company. Pfizer purchased all outstanding shares of Metsera stock at $65.60 per share, an enterprise valuation of about $7 billion, with additional contingent value right (CVR) payments of $20.65 per share that are tied to Metsera hitting certain clinical and regulat…
Pfizer completes up to $10 billion acquisition of Metsera
Pfizer on Thursday closed its up to $10 billion acquisition of Metsera after winning shareholder approval, gaining a foothold in the fast-growing obesity market following a fierce bidding war with Novo Nordisk .
Pfizer CEO vows company will be a ‘formidable competitor’ in booming weight-loss market after $10B buy
Pfizer Inc. is doubling down on the booming weight-loss drug race, with CEO Albert Bourla declaring the company will be a "formidable competitor" after securing a $10 billion deal to acquire obesity-drug developer Metsera."Pfizer, when it plays, plays big, and we will, as we did in COVID, as with Lipitor, as [with] Viagra, with all the medicines that we have invented and brought to the market, we will do the same with obesity," Bourla said Thurs…
Pfizer Completes $10 Billion Metsera (MTSR) Buyout as Nasdaq Delists Stock Today
Metsera Inc. (NASDAQ: MTSR) stops trading today, November 14, 2025, as Pfizer closes its up to $10 billion obesity-drug acquisition. Here’s what Metsera shareholders and obesity-market investors need to know about the deal terms, CVR, delisting, and future milestones. Date: November 14, 2025Ticker: MTSR (Metsera, Inc.) – now being delisted On Friday, November 14, 2025, Metsera, Inc. officially disappears from the Nasdaq tape. Trading in Metsera …
After winning the bidding war against Novo Nordisk, Pfizer has announced the completion of its acquisition of the biotech company Metsera. For Pfizer CEO Albert Bourla, the purchase is strategically very important.
Coverage Details
Bias Distribution
- 55% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
